Celgene’s investigational therapy ozanimod is showing promise for lowering MS relapse rates.
A Phase 3 clinical trial evaluating the safety and effectiveness of ozanimod (RPC-1063) in patients with relapsing multiple sclerosis (RMS) shows treatment reduced the disease’s annualized relapse rate (ARR), researchers reported.
The Phase 3 SUNBEAM trial (NCT02294058) tested ozanimod, an oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator designed to treat immune-inflammatory conditions such as RMS. Lowering ARR was this study’s primary goal for the treatment, being developed by Celgene Corporation.
Those with RMS can experience relapses — also called flare-ups or exacerbations — that worsen their neurologic function. Relapses are usually followed by partial or complete recovery periods, called remissions, during which symptoms cease or partially improve, and the disease appears to stabilize.
Ozanimod works by binding to S1PR1 and S1PR5 receptors. The binding inhibits certain lymphocytes, or immune cells, from migrating to sites of inflammation. This reduces circulating T- and B-lymphocytes, stabilizing immune function.
Read full article: Multiple Sclerosis Relapse Rate Falls With Ozanimod Therapy, Trial Shows
|Read Full Article: Multiple Sclerosis Relapse Rate Falls With Ozanimod Therapy, Trial Shows|